Clinical and methodological considerations on the results of the SENSCIS trial: Comment on the article by Maher et al

I read with interest the reanalysis of the results of the SENSCIS trial, published by Maher et al (1). The article may represent an advance in the knowledge of the effects of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD), but there are aspects that deserve additional comments.